Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study

de Martel, 2012, Global burden of cancers attributable to infections in 2008: a review and synthetic analysis, Lancet Oncol, 13, 607, 10.1016/S1470-2045(12)70137-7 Bartelink, 1997, J Clin Oncol, 15, 2040, 10.1200/JCO.1997.15.5.2040 Flam, 1996, Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study, J Clin Oncol, 14, 2527, 10.1200/JCO.1996.14.9.2527 Das, 2007, Predictors and patterns of recurrence after definitive chemoradiation for anal cancer, Int J Radiat Oncol Biol Phys, 68, 794, 10.1016/j.ijrobp.2006.12.052 Eng, 2006, Anal cancer: current and future methodology, Cancer Invest, 24, 535, 10.1080/07357900600815208 Frisch, 1997, Sexually transmitted infection as a cause of anal cancer, N Engl J Med, 337, 1350, 10.1056/NEJM199711063371904 Morris, 2015, Clinicopathologic features associated with human papillomavirus/p16 in patients with metastatic squamous cell carcinoma of the anal canal, Oncologist, 20, 1247, 10.1634/theoncologist.2015-0091 Daling, 2004, Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer, Cancer, 101, 270, 10.1002/cncr.20365 Hoots, 2009, Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions, Int J Cancer, 124, 2375, 10.1002/ijc.24215 Saslow, 2016, Human papillomavirus vaccination guideline update: American Cancer Society guideline endorsement, CA Cancer J Clin, 66, 375, 10.3322/caac.21355 Reagan-Steiner, 2016, National, regional, state, and selected local area vaccination coverage among adolescents aged 13–17 years—United States, 2015, MMWR Morb Mortal Wkly Rep, 65, 850, 10.15585/mmwr.mm6533a4 Viens, 2016, Human papillomavirus-associated cancers—United States, 2008–2012, MMWR Morb Mortal Wkly Rep, 65, 661, 10.15585/mmwr.mm6526a1 Scheffner, 1990, The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53, Cell, 63, 1129, 10.1016/0092-8674(90)90409-8 Werness, 1990, Association of human papillomavirus types 16 and 18 E6 proteins with p53, Science, 248, 76, 10.1126/science.2157286 Balsitis, 2003, Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo, Mol Cell Biol, 23, 9094, 10.1128/MCB.23.24.9094-9103.2003 Welters, 2003, Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter, Cancer Res, 63, 636 de Jong, 2004, Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6, Cancer Res, 64, 5449, 10.1158/0008-5472.CAN-04-0831 Ishida, 1992, Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, EMBO J, 11, 3887, 10.1002/j.1460-2075.1992.tb05481.x Freeman, 2000, Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation, J Exp Med, 192, 1027, 10.1084/jem.192.7.1027 Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Motzer, 2015, Nivolumab versus everolimus in advanced renal-cell carcinoma, N Engl J Med, 373, 1803, 10.1056/NEJMoa1510665 Robert, 2015, Nivolumab in previously untreated melanoma without BRAF mutation, N Engl J Med, 372, 320, 10.1056/NEJMoa1412082 Ferris, 2016, Further evaluations of nivolumab (nivo) versus investigator's choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141, Proc Am Soc Clin Oncol, 34 Eisenhauer, 2009, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur J Cancer, 45, 228, 10.1016/j.ejca.2008.10.026 Lanman, 2015, Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA, PLoS One, 10, e0140712, 10.1371/journal.pone.0140712 Greenwood, 1926 Altman, 1991 Wolchok, 2009, Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria, Clin Cancer Res, 15, 7412, 10.1158/1078-0432.CCR-09-1624 Ajani, 1989, Combination of cisplatin plus fluoropyrimidine chemotherapy effective against liver metastases from carcinoma of the anal canal, Am J Med, 87, 221, 10.1016/S0002-9343(89)80702-8 Faivre, 1999, 5-fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer, Bull Cancer, 86, 861 Eng, 2014, The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal, Oncotarget, 5, 11133, 10.18632/oncotarget.2563 Chung, 2016, Comprehensive genomic profiling of anal squamous cell carcinoma reveals distinct genomically defined classes, Ann Oncol, 27, 1336, 10.1093/annonc/mdw152 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954